[1] Krejs G J. Gastric cancer: epidemiology and risk factors[J]. Dig Dis, 2010, 28(4-5): 600-603.
[2] Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity[J]. J Gastrointest Oncol, 2011, 2(2): 77-84.
[3] Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer[J]. Br J Surg, 2013, 100(1): 55-65.
[4] 朱圣韬, 曹邦伟, 徐昌青,等. TIM-3基因启动子区多态性与胃癌易感的相关性研究[J]. 首都医科大学学报,2010, 31(3): 299-303.
[5] Cervantes A, Roda D, Tarazona N, et al. Current questions for the treatment of advanced gastric cancer[J]. Cancer Treat Rev, 2013, 39(1): 60-67.
[6] 曹邦伟, 于晶琳, 荷欢,等. 中国人群中HPV感染与食管癌发生关联的Meta分析[J]. 首都医科大学学报, 2010, 31(2): 258-263.
[7] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997, 315(7109): 629-634.
[8] 陈绍俊,黄海欣,李桂生. 卡培他滨与氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗晚期胃癌的随机对照临床研究[J]. 中国癌症杂志,2007, 17(6): 483-486.
[9] 胡建兵,文芳,翁洁. XELOX和OLF方案治疗晚期胃癌的随机对照临床研究[J]. 中国实用医药,2009, 4(15): 25-26.
[10] 雷俊华,洪涛,曾江正,等. XELOX方案治疗进展期胃癌临床观察[J]. 华北国防医药,2009, 21(4): 10-12.
[11] 刘风玲,郑毅琳. 奥沙利铂联合卡培他滨或氟脲嘧啶/叶酸方案治疗晚期胃癌的临床疗效比较[J]. 实用临床医药杂志,2010, 14(23): 50-51.
[12] 陆海林,李燕,宁志强,等. XELOX与FOLFOX4方案治疗晚期胃癌疗效观察[J]. 实用临床医药杂志,2011, 15(19): 112-113.
[13] 曲智锋,冯笑山,高社干,等. 奥沙利铂联合卡培他滨治疗晚期胃癌临床疗效观察[J]. 福建医药杂志,2007, 29(4): 41-43.
[14] 孙清,毛永杰,赵伟,等. 卡培他滨联合奥沙利铂治疗晚期胃癌的随机对照临床研究[J]. 肿瘤防治研究,2005, 32(11): 729-730.
[15] 王爱英,张毛讲. 卡培他滨联合奥沙利铂治疗晚期胃癌的临床观察[J]. 中国医药导报,2012, 9(6): 58-59.
[16] 王红民,程先鸣, 张明莉. 奥沙利铂加卡培他滨治疗晚期胃癌的疗效观察[J]. 中国医院用药评价与分析,2009, 9(11): 856-857.
[17] 王海忠,王湘辉,吕志诚. XELOX与FOLFOX4方案治疗进展期胃癌的随机对照临床研究[J]. 现代肿瘤医学,2010, 18(15): 947-950.
[18] 王磊,胡冰,季楚舒,等. XELOX与FLO方案治疗晚期胃癌的近期疗效及毒副反应比较[J]. 安徽医药,2011, 15(3): 329-330.
[19] 杨晶. 卡培他滨联合奥沙利铂在晚期胃癌中的临床效果研究[J]. 实用心脑肺血管病杂志,2011, 19(3): 369-370.
[20] 赵文英,吉兆宁. XELOX或FOLFOX4方案治疗晚期胃癌的随机对照分析[J]. 中国肿瘤临床,2009, 36(18): 1044-1046.
[21] Francesco M, Gina T, Claudio M, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer, 2011, 14(1): 50-55.
[22] Hirsch B R, Zafar S Y. Capecitabine in the management of colorectal cancer[J]. Cancer Manag Res, 2011, 3: 79-89.
[23] Kang Y K, Kang W K, Shin D B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase Ⅲ noninferiority trial[J]. Ann Oncol, 2009, 20(4): 666-673.
[24] Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results[J]. Br J Cancer, 2011, 105(1): 58-64.
[25] Caronia D, Martin M, Sastre J, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J]. Clin Cancer Res, 2011, 17(7): 2006-2013.
[26] Azuma Y, Hata K, Sai K, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer[J]. Biol Pharm Bull, 2012, 35(5): 717-724.
[27] 肖作珍,肖瑞,姜继臣.奥沙利铂联合表柔比星和5-Fu治疗多发转移性胃癌的临床观察[J].中华肿瘤防治杂志,2010,17(12):946-947.
[28] 严冬,戴红.恩度联合XELOX方案一线治疗老年晚期结直肠癌的临床观察[J].中华肿瘤防治杂志,2011,18(12):961-964.
[29] 柴慈婧,王骏飞,李罡,等.卡培他滨治疗老年晚期消化道肿瘤的临床观察[J].中华肿瘤防治杂志,2010,17(19):1571-1572,1575. |